Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age. (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024)